[Federal Register Volume 67, Number 36 (Friday, February 22, 2002)]
[Notices]
[Pages 8273-8274]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-4378]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Vaccines and Related Biological Products Advisory Committee; 
Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    Name of Committee: Vaccines and Related Biological Products 
Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held by teleconference on March 
6, 2002, from 12:30 p.m. to 4:30 p.m.
    Location: Food and Drug Administration, Bldg. 29, conference room 
121, 8800 Rockville Pike, Bethesda, MD. This meeting will be held by a 
telephone conference call. A speaker telephone will be provided in the 
conference room to allow public participation in the meeting.
    Contact Person: Jody G. Sachs or Denise H. Royster, Center for 
Biologics Evaluation and Research (CBER) (HFM-71), Food and Drug 
Administration,

[[Page 8274]]

1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), code 12391. Please call the Information Line for 
up-to-date information on this meeting.
    Agenda: The committee will complete recommendations pertaining to 
the influenza virus vaccine formulation for the 2002-2003 season, and 
review and discuss the research programs of the following two CBER 
Laboratories: Laboratories of Hepatitis Virus and the Laboratory of 
Vector-borne Viral Diseases.
    Procedure: On March 6, 2002, from 12:30 p.m. to 3:30 p.m., the 
meeting is open to the public. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Written submissions may be made to the contact person by 
February 25, 2002. Oral presentations from the public will be scheduled 
between approximately 2 p.m. and 2:30 p.m., and between approximately 3 
p.m. and 3:30 p.m. Time allotted for each presentation may be limited. 
Those desiring to make formal oral presentations should notify the 
contact person before February 25, 2002, and submit a brief statement 
of the general nature of the evidence or arguments they wish to 
present, the names and addresses of proposed participants, and an 
indication of the approximate time requested to make their 
presentation.
    Closed Committee Deliberations: On March 6, 2002, from 3:30 p.m. to 
4:30 p.m., the meeting will be closed to permit discussion where 
disclosure would constitute a clearly unwarranted invasion of personal 
privacy (5 U.S.C. 552b(c)(6)). The meeting will be closed to discuss 
personal information concerning individuals associated with the 
research programs.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Jody G. Sachs or 
Denise H. Royster at least 7 days in advance of the meeting.
    FDA regrets that it was unable to publish this notice 15 days prior 
to the Vaccines and Related Biological Products Advisory Committee 
meeting. Because the agency believes there is some urgency to bring 
these issues to public discussion and qualified members of the Vaccines 
and Related Biological Products Advisory Committee were available at 
this time, the Commissioner of Food and Drugs concluded that it was in 
the public interest to hold this meeting even if there was not 
sufficient time for the customary 15-day public notice.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: February 17, 2002.
Linda A. Suydam,
Senior Associate Commissioner for Communications and Constituent 
Relations.
[FR Doc. 02-4378 Filed 2-20-02; 1:27 pm]
BILLING CODE 4160-01-S